314,552 interview questions from 6,000+ companies.
Tests whether you can translate technical complexity into business-relevant language for non-technical stakeholders and drive action.
Tests conflict resolution in a delivery context, including communication, influence without authority, and ability to preserve team trust while reaching a decision.
Tests adaptability under changing requirements, including reprioritization, ownership, and execution in ambiguity.
Tests influence without authority when data conflicts with senior judgment, including stakeholder management and clear communication.
Tests how you lead through ambiguity, re-prioritize under changing conditions, and maintain ownership while aligning stakeholders.
Tests prioritization under pressure, stakeholder management, and decision-making when multiple teams compete for limited analyst capacity.
Tests motivation and alignment with Exelixis mission and drug development work.
Tests your ability to adapt research strategy when biology data contradicts expectations.
Tests learning from failure and implementing concrete improvements to experimental execution.
Tests your end-to-end assay development understanding, including design, execution, and troubleshooting.
Tests hands-on biological technique depth relevant to Exelixis research needs.
Tests experimental design thinking for validating drug targets in a biotech pipeline context.
Tests your ability to control, quantify, and mitigate variability to ensure reliable results.
Tests clarity, translation skills, and communication effectiveness across audiences.
Tests your approach to diagnosing technical issues and improving data quality at scale.
Tests decision-making under uncertainty and your criteria for changing direction.
Tests prioritization and time management across wet lab work and data responsibilities.
Tests your ability to apply and develop assays to address difficult biological questions.
Tests root-cause analysis skills and structured scientific reasoning.
Tests your habits for continuous learning and staying aligned with oncology advances.
